Kenichi Harada

9PUBLICATIONS
19CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Mar 01, 2024
Clinical outcomes in patients with advanced urothelial carcinoma treated with enfortumab vedotin: A retrospective multicenter study in Japan.

Takuto Hara, Yuto Matsushita, Kenichi Harada

|Jun 22, 2023
Efficacy and safety of pembrolizumab and axitinib as first-line treatment for patients with advanced renal cell carcinoma: Real-world experience in Japan.

Ken-Ichi Harada, Ryo Sato, Yukari Bando

|Jun 15, 2023
The poor antitumor effect of pembrolizumab in advanced upper urothelial carcinoma with renal parenchymal invasion.

Takuto Hara, Junya Furukawa, Yasuyoshi Okamura

|May 02, 2023
Impact of cytoreductive nephrectomy prior to combination therapy of ipilimumab plus nivolumab in metastatic renal cell carcinoma.

Takuto Hara, Junya Furukawa, Yusuke Shiraishi

|Feb 01, 2023
Utility of prognostic prediction by early assessment of response to combined treatment with nivolumab plus ipilimumab in patients with treatment-naïve metastatic renal cell carcinoma.

Ken-Ichi Harada, Hideaki Miyake, Junya Furukawa

|Dec 28, 2022
Significance of second progression-free survival in patients with advanced urothelial cancer who received platinum-based combination chemotherapy followed by pembrolizumab.

Ryo Sato, Teruo Inamoto, Yuto Matsushita

Pageof 2

Frequent Collaborators

4 joint publications

Naohiro Fujimoto

4 joint publications

Yukari Bando

4 joint publications

Tomoaki Terakawa

4 joint publications

Takuto Hara